Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tisotumab vedotin-tftv |
| Trade Name | Tivdak |
| Synonyms | HuMax-TF-ADC|TF-011-MMAE |
| Drug Descriptions |
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 1418731-10-8 |
| NCIT ID | C113164 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Tisotumab vedotin-tftv | Bevacizumab Tisotumab vedotin-tftv | 0 | 1 |
| Carboplatin + Tisotumab vedotin-tftv | Carboplatin Tisotumab vedotin-tftv | 0 | 1 |
| Pembrolizumab + Tisotumab vedotin-tftv | Pembrolizumab Tisotumab vedotin-tftv | 0 | 1 |
| Tisotumab vedotin-tftv | Tisotumab vedotin-tftv | 0 | 7 |